Anti‐Ro52 Antibodies in Clinical Practice: A Single‐centre Experience

Si Wu,Xiaojun Tang,Liping Wu,Liangjing Lu,Xuebing Feng
DOI: https://doi.org/10.1111/ijcp.13679
IF: 2.6
2021-01-01
International Journal of Clinical Practice
Abstract:Introductions: To analyse the clinical significance of anti-Ro52 autoantibodies that target TRIM21 protein and occur in a variety of connective tissue diseases (CTD), 4782 cases with blood tested positive for anti-Ro52 antibodies between January 2016 and September 2017 in Drum Tower Hospital were enrolled. Methods: Anti-Ro52 and anti-Ro60 were measured using the immunoblotting method together with antibodies against other extractable nuclear antigens at the time of the patient's first visit. Results: In this cohort, females accounted for the majority of all subjects (75.9%) and the average age was 47.25 years old. About 97.4% were diagnosed as having various diseases, in which around 2/3 were CTDs. The incidence of CTD in patients with merely anti-Ro52 was lower than those with both anti-Ro52 and anti-Ro60 (54.7% vs 85.5% for all patients and 53.3% vs 87.1% for inpatients, bothP < .0001). Amongst CTDs, the incidence of systemic lupus erythematosus was significantly decreased, while the incidence of inflammatory myositis as well as undifferentiated connective tissue diseases was increased in anti-Ro52 single-positive group. For patients with either CTDs or non-CTDs, respiratory involvement was more common in patients with merely anti-Ro52 (67.6% vs 34.7%,P < .0001 and 53.2% vs 36.3%,P < .01). Sub-analysis revealed that both interstitial lung disease and pulmonary infection were related to anti-Ro52 in CTD inpatients (P P < .05). Conclusions: Our study shows that anti-Ro52 could occur in various clinical conditions. These antibodies may appear in the early stage of CTD with the lung an important target organ, thus their presence warrants long-term follow-up.
What problem does this paper attempt to address?